Abstract
Clinical EndocrinologyVolume 92, Issue 2 p. 182-182 CORRIGENDUMFree Access Corrigendum This article corrects the following: BRAF mutation analysis by ARMS-PCR refines thyroid nodule management Xinyang Li, Enling Li, Jing Du, Jiadong Wang, Bing Zheng, Volume 91Issue 6Clinical Endocrinology pages: 834-841 First Published online: October 1, 2019 First published: 13 January 2020 https://doi.org/10.1111/cen.14139AboutSectionsPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinkedInRedditWechat In the published article of Xinyang Li et al1 included in December 2019 issue (CEN v91 i6), ‘BRAF mutation analysis by ARMS-PCR refines thyroid nodule management’, it has been brought to the authors’ attention that there were some items that need changes in Table 2, Abstract (Results), Section 3.2 (BRAF mutation status and surgery patient profiles) and Section 4 (Discussion). Table 2. Clinical profiles of 925 surgery patients Clinicopathological features Sex (male) 239 (25.8) Age at surgery (mean ± SD), y 46.5 ± 12.9 BRAFV600E patients PTC (n = 777) 684 (88.0) FTC (n = 4) 0 (0.0) MTC (n = 3) 1 (0.3) Benign tumour (n = 141) 26 (18.4) Tumour size of MT (mean ± SD), mm 7.7 ± 6.3 CLNM of MT (n = 784) 269 (34.3) LLNM in MT (n = 784) 43 (5.5) Changes made are written below: In Table 2, under PTC (n = 777), the correct value is 684 (88.0) In Abstract (Results), Section 3.2 (BRAF mutation status and surgery patient profiles) and Section 4 (Discussion), the proportion of BRAFV600E mutation-positive cases in PTC patients should be ‘88.0%’ rather than ‘86.7%’. The authors would like to apologize for this omission and convey the above additional information. REFERENCE 1Li X, Li E, Du J, Wang J, Zheng B BRAF mutation analysis by ARMS-PCR refines thyroid nodule management. Clin Endocrinol (Oxf). 2019; 91: 834- 841. https://doi.org/10.1111/cen.14079. Volume92, Issue2February 2020Pages 182-182 ReferencesRelatedInformation
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
